Library · Metabolic & weight · Treatment of obesity and type 2 diabetes
Dapiglutide (ZP7570)
ZP7570, ZP-7570
Investigational dual GLP-1/GIP receptor agonist peptide (ZP7570) from the early 2020s, designed for enhanced metabolic benefit over single-receptor incretins. In early clinical development for type 2 diabetes and obesity, with once-weekly dosing under study; preclinical data show reduced glucose and body weight in animals.
Research score 85/100. Reference only, not a dose.
- GLP-1 Agonist
- GIP Agonist
- Appetite Suppression
- Blood Sugar Control
- Metabolic Enhancement
- US status
- Investigational
- Approval
- Phase 1/2 Clinical Trial
- Evidence
- Long-acting GLP-1/GLP-2 dual agonist. Investigational for obesity and improving intestinal barrier function.
- Research score
- 85 / 100
- Indication
- Investigational - Type 2 Diabetes Mellitus
- Origin
- Denmark
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
Activates both GLP-1 and GIP receptors, raising cAMP/PKA signaling to boost glucose-dependent insulin release, cut glucagon secretion, and slow gastric emptying; structural changes extend half-life and resist DPP-4 breakdown.
Safety file
Mostly mild-to-moderate nausea and vomiting, with some mild injection-site reactions; anti-drug antibodies appeared in about 14% of participants, with no serious drug-related events reported early on.
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Decreased appetite